On May 21, 2020, Abbott announced an interim analysis of an ongoing multi-site clinical study in urgent care clinics that indicates its ID NOW COVID-19 rapid test is showing strong agreement to lab-based molecular polymerase chain reaction (PCR) instruments.

The interim results demonstrated the ID NOW COVID-19 test performance was =94.7% in positive agreement (sensitivity) and =98.6% negative agreement (specificity) when compared to two different lab-based PCR reference methods.